Glooko is a healthcare technology company which offers a diabetes management platform to healthcare providers, patients, and pharmaceutical companies. The platform is designed to integrate with hundreds of diabetes devices to gather and analyze patient data. Through comprehensive data centralization and analytical tools, Glooko aims to enhance diabetes management and facilitate clinical research in the field. This company was founded by Yogen Dalal, Sundeep Madra, and Chamath Palihapitiya in 2010 and is headquartered in Palo Alto, CA.

Register for Details

For more details on financing and valuation for Glooko, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn More About Glooko

To invest in Glooko pre-IPO

Can you invest in Glooko pre-IPO?

Glooko is a privately held company and is not publicly traded, therefore investing in Glooko pre-IPO is only available to accredited investors. If you meet the accreditation criteria, you can learn more about Forge’s Secondary Marketplace and how to invest in private companies before their potential IPO. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.

Can you sell shares of Glooko before it goes public?

You can seek to sell your shares in Glooko while it remains private. If you are considering selling, you can register today for free to get started. Once registered, a Private Market Specialist will guide you through any questions you might have. You may also continue to browse through our resources to help you understand the implications and procedures involved in selling your private market shares.

What is the pre-IPO value of my Glooko shares?

To determine the value of your Glooko shares, create a free account to gain access to Forge’s platform. In addition to the Forge Price, Forge Markets contains pricing information for hundreds of pre-IPO companies such as Last Closed Trade Price. A Private Market Specialist will also be available to assist you with any inquiries related to your Glooko shares. You can also learn more about how to sell your private shares before getting started.

Is Glooko a publicly traded company?

If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.

To learn more about Glooko potential IPO

Will Glooko go IPO?

Glooko has not yet filed for an IPO. However, it’s important to note that IPOs are not the sole avenue for a private company to transition to public trading. Private companies can also go public through alternative methods such as but limited to Special Purpose Acquisition Companies (SPACs), direct listings, or mergers and acquisitions. Find out which companies are eyeing an IPO on our Tech IPO Calendar 2024.

What is Glooko’s IPO price?

The Glooko IPO price does not exist at this time, as Glooko is still a private company and has not yet conducted an IPO. To explore secondary market data and access private market pricing details and data that may be related to Glooko register for Forge Markets, today.

When was Glooko founded?

Glooko was founded in 2010.

What is Glooko funding to date?

Glooko has raised $521.83MM to date.

Who are Glooko’s major investors?

Health Catalyst Capital
Novo Nordisk
Georgian
Insulet
Mayo Clinic
Yogen Dalal
Samsung Next Ventures
Venky Harinarayan
Georgian Partners
Xtreme Labs
Realization Capital Partners
Canaan Partners
Bill Campbell
Medtronic
Venky Harinarayan and Annad Rajaraman
Social Capital
Russell Hirsch
Health Catalyst Capital Management
Canaan
Sundeep Madra
Andy Hertzfeld
Russel Hirsch
Lifeforce Ventures
Judy Estrin
Anand Agarawala
Vint Cerf
Undisclosed Investors
Samsung

Glooko Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
10/10/2024 Series F $100MM $xx.xx $475.64MM Canaan, Georgian Partners, Health Catalyst Capital
Price per Share
$xx.xx
Shares Outstanding
41,407,867
Liquidation Pref Order
1
Liquidation Pref As Multiplier
2.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Canaan, Georgian Partners, Health Catalyst Capital
08/18/2023 Series E-Prime $30.56MM $xx.xx $318.34MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
12,652,982
Liquidation Pref Order
2
Liquidation Pref As Multiplier
2.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
08/18/2023 Series E $30.56MM $xx.xx $318.34MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
12,652,982
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
03/16/2021 Series D-Prime $10MM $xx.xx $150.67MM Canaan Partners, Georgian, Health Catalyst Capital, Insulet, Mayo Clinic, Novo Nordisk
Price per Share
$xx.xx
Shares Outstanding
7,510,886
Liquidation Pref Order
2
Liquidation Pref As Multiplier
2.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Canaan Partners, Georgian, Health Catalyst Capital, Insulet, Mayo Clinic, Novo Nordisk
03/16/2021 Series D $20MM $xx.xx $150.67MM Canaan Partners, Georgian, Health Catalyst Capital, Insulet, Mayo Clinic, Novo Nordisk
Price per Share
$xx.xx
Shares Outstanding
15,021,772
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Canaan Partners, Georgian, Health Catalyst Capital, Insulet, Mayo Clinic, Novo Nordisk
06/27/2017 Series C-1-Prime $13.01MM $xx.xx $116.76MM Canaan Partners, Georgian Partners, Insulet, Mayo Clinic, Medtronic, Samsung, Social Capital
Price per Share
$xx.xx
Shares Outstanding
10,335,930
Liquidation Pref Order
2
Liquidation Pref As Multiplier
2.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Canaan Partners, Georgian Partners, Insulet, Mayo Clinic, Medtronic, Samsung, Social Capital
06/27/2017 Series C-1 $13.29MM $xx.xx $116.76MM Canaan Partners, Georgian Partners, Insulet, Mayo Clinic, Medtronic, Samsung, Social Capital
Price per Share
$xx.xx
Shares Outstanding
10,562,032
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Canaan Partners, Georgian Partners, Insulet, Mayo Clinic, Medtronic, Samsung, Social Capital
09/17/2016 Series C-Prime $8.35MM $xx.xx $135.3MM Canaan Partners, Samsung, Social Capital, Yogen Dalal
Price per Share
$xx.xx
Shares Outstanding
4,130,876
Liquidation Pref Order
2
Liquidation Pref As Multiplier
2.0x
Conversion Ratio
1.1x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Canaan Partners, Samsung, Social Capital, Yogen Dalal
09/17/2016 Series C $8.35MM $xx.xx $135.3MM Canaan Partners, Samsung, Social Capital, Yogen Dalal
Price per Share
$xx.xx
Shares Outstanding
4,130,876
Liquidation Pref Order
5
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.1x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Canaan Partners, Samsung, Social Capital, Yogen Dalal
03/17/2015 Series B-Prime $8.25MM $xx.xx $85.02MM Canaan Partners, Medtronic, Samsung, Social Capital
Price per Share
$xx.xx
Shares Outstanding
6,061,808
Liquidation Pref Order
2
Liquidation Pref As Multiplier
2.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Canaan Partners, Medtronic, Samsung, Social Capital
03/17/2015 Series B $8.25MM $xx.xx $85.02MM Canaan Partners, Medtronic, Samsung, Social Capital
Price per Share
$xx.xx
Shares Outstanding
6,061,808
Liquidation Pref Order
6
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Canaan Partners, Medtronic, Samsung, Social Capital
01/08/2014 Series A-1-Prime $3.5MM $xx.xx $25.22MM Lifeforce Ventures, Samsung, Social Capital, Sundeep Madra, Yogen Dalal
Price per Share
$xx.xx
Shares Outstanding
4,504,968
Liquidation Pref Order
2
Liquidation Pref As Multiplier
2.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Lifeforce Ventures, Samsung, Social Capital, Sundeep Madra, Yogen Dalal
01/08/2014 Series A-1 $3.5MM $xx.xx $25.22MM Lifeforce Ventures, Samsung, Social Capital, Sundeep Madra, Yogen Dalal
Price per Share
$xx.xx
Shares Outstanding
4,504,968
Liquidation Pref Order
7
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Lifeforce Ventures, Samsung, Social Capital, Sundeep Madra, Yogen Dalal
01/30/2012 Series A-Prime $1.15MM $xx.xx $29.2MM Andy Hertzfeld, Bill Campbell, Judy Estrin, Russell Hirsch, Social Capital, Venky Harinarayan, Vint Cerf, Xtreme Labs
Price per Share
$xx.xx
Shares Outstanding
115,000
Liquidation Pref Order
2
Liquidation Pref As Multiplier
2.0x
Conversion Ratio
5.6x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Andy Hertzfeld, Bill Campbell, Judy Estrin, Russell Hirsch, Social Capital, Venky Harinarayan, Vint Cerf, Xtreme Labs
01/30/2012 Series A $1.15MM $xx.xx $29.2MM Andy Hertzfeld, Bill Campbell, Judy Estrin, Russell Hirsch, Social Capital, Venky Harinarayan, Vint Cerf, Xtreme Labs
Price per Share
$xx.xx
Shares Outstanding
115,000
Liquidation Pref Order
8
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
5.6x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Andy Hertzfeld, Bill Campbell, Judy Estrin, Russell Hirsch, Social Capital, Venky Harinarayan, Vint Cerf, Xtreme Labs
11/09/2011 Series Seed-Prime $500,000.00 $xx.xx $5MM Anand Agarawala, Andy Hertzfeld, Bill Campbell, Judy Estrin, Russel Hirsch, Social Capital, Venky Harinarayan and Annad Rajaraman, Vint Cerf, Xtreme Labs
Price per Share
$xx.xx
Shares Outstanding
250,000
Liquidation Pref Order
2
Liquidation Pref As Multiplier
2.0x
Conversion Ratio
2.1x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Anand Agarawala, Andy Hertzfeld, Bill Campbell, Judy Estrin, Russel Hirsch, Social Capital, Venky Harinarayan and Annad Rajaraman, Vint Cerf, Xtreme Labs
11/09/2011 Series Seed $500,000.00 $xx.xx $5MM Anand Agarawala, Andy Hertzfeld, Bill Campbell, Judy Estrin, Russel Hirsch, Social Capital, Venky Harinarayan and Annad Rajaraman, Vint Cerf, Xtreme Labs
Price per Share
$xx.xx
Shares Outstanding
250,000
Liquidation Pref Order
8
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
2.1x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Anand Agarawala, Andy Hertzfeld, Bill Campbell, Judy Estrin, Russel Hirsch, Social Capital, Venky Harinarayan and Annad Rajaraman, Vint Cerf, Xtreme Labs
Updated on: Dec 22, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.